ADPT insider filing: proposed resale of Common Stock by Francis Lo under Rule 144 and 10b5-1 plan. The filing lists multiple recent sales by Francis Lo, including 38,074 shares on 03/05/2026 for $574,536.66 and earlier 10b5-1 sales of 79,590 shares on 01/12/2026 for $1,411,393.35. The record also lists 30,593 Restricted Stock Units dated 03/04/2025.
Michelle Griffin reported sales of Common Stock. The filing shows Ms. Griffin disposed of 48,044 shares on 03/03/2026 for $735,299.01. The form also lists 15,394 restricted shares associated with Morgan Stanley Smith Barney LLC dated 03/04/2026.
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported an exercise-and-sell trading pattern in March 2026. She exercised stock options for a total of 68,328 shares of Common Stock at exercise prices of $6.55 and $12.14 per share, then sold 81,342 shares in open-market transactions.
The sales occurred on March 6, 9 and 10, 2026 at weighted-average prices including $15.14, $14.79 and $14.68 per share. All transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 643,471 shares of Common Stock.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice registering 38,074 shares of Common stock to be sold, labeled as RSUs with an effective date of 03/04/2026.
The filing also lists recent 10b5-1 sales attributable to Francis Lo, including 79,590 shares on 01/12/2026 and 3,125 shares on 01/02/2026.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an automatic share sale tied to equity compensation. On the RSU vesting date, 38,074 shares of common stock were sold to cover tax withholding obligations under a mandated “sell to cover” arrangement, rather than as a discretionary trade.
After this tax-related sale, Francis Lo directly owned 321,967 common shares. An additional 2,500 common shares were reported as indirectly owned through Lo’s spouse, You Jin Lee.
Adaptive Biotechnologies Corp director Peter M. Neupert reported an acquisition of common stock through a grant or award. On March 4, 2026, he received 15,625 shares at a stated price of $0.0000 per share, bringing his directly owned holdings to 240,315 shares of common stock.
Adaptive Biotechnologies Corp director Robert Hershberg reported an award of common stock. On March 4, 2026, he acquired 15,625 shares of common stock through a grant with a stated price of $0.00 per share. Following this award, his direct holdings total 62,347 shares of common stock.
Adaptive Biotechnologies Corp reported that its Chief People Officer, Francis Lo, acquired 44,063 shares of common stock on March 4, 2026 through a stock grant at no cost, described as a grant, award, or other acquisition. Following this equity award, Lo directly holds 360,041 common shares. The filing also notes an additional 2,500 common shares held indirectly through Lo’s spouse, You Jin Lee.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky received two awards of common stock on March 4, 2026. She acquired 59,375 shares in one grant and 62,500 shares in another, both at a reported price of $0.00 per share, increasing her directly held stake.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, Immune Medicine, Sharon Benzeno acquired 39,063 shares of common stock on March 4, 2026 through a grant or award at a stated price of $0.00 per share. Following this award, Benzeno directly holds 335,854 common shares.